Dr. Yoichi Kato | Asia Immunotherapy | Authority on Immune Cell Therapy - Dr. Yoichi Kato

1992 – Graduated with an M.D. from Nihon University (Japan) 

1995–1999 – National Cancer Center of Japan (a national authority), leading immunotherapy development 

1999 – Earned a Ph.D. in Medicine from Nihon University 

2006–2008 – Lecturer in Surgery, Tokyo Women’s Medical University 

2008–Present – Director, Shin-Yokohama Kato Clinic 

2010–Present – Chairman, Shinjukai Medical Corporation 

2011–Present – Lecturer in Radiology, St. Marianna University School of Medicine 

2011–Present – Delegate, Yokohama Medical Association 

2011–Present – Delegate, Kanagawa Prefecture Medical Association 

2011–2015 – Chairman, Yokohama Kohoku Medical Center 

2015–Present – Vice Chairman, Yokohama Kohoku Medical Association 

2017–Present – Vice President, Yokohama Surgical Association 

2019–Present – Consultant, Vectorite Biotech Inc (Taiwan; Ticker Symbol: 4170) 

2022–Present – Partner and Chief Advisor, Asia Immunotherapy (Hong Kong) 

2024–Present – Vice Chairman, Kanagawa Welfare Service Promotion Association (公益社団法人かながわ福祉サービス振興会)

About Dr. Yoichi Kato 

Dr. Yoichi Kato is a highly experienced oncologist and a leading figure in the field of immunotherapy in Japan. From 1995 to 1999, Dr. Kato conducted pioneering research at Japan’s National Cancer Center, advancing immunocellular therapy and treating numerous cancer patients. In 2008, he established the Shin-Yokohama Kato Clinic, which has since accumulated a substantial number of clinical cases—making Dr. Kato one of Japan’s most experienced physicians in administering immunotherapy. To date, his treatments have proved effective in 68% of late-stage cancer patients, with 8% achieving complete remission (CR, or total tumor disappearance).  

(Dr. Kato medical building)

Dr. Kato has published over 25 academic papers internationally and authored multiple books, exemplifying his dual expertise in research and clinical application. His specialized fields include Dendritic Cell (DC) therapy, LAK (Lymphokine-Activated Killer) cell therapy, and advanced NK therapy—providing a broad spectrum of immunocellular treatments targeted at different cancer types.